> ## Content Index
> Fetch the complete content index at: https://www.pharmamanufacturingiq.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Eramol announces sterile manufacturing facility to open in 2026
- URL: https://www.pharmamanufacturingiq.com/eramol-announces-sterile-manufacturing-facility-to-open-in-2/
- Published: 2025-07-31T14:30:00.000Z
- Updated: 2026-10-08T12:39:54.000Z
- Description: Eramol, a UK-based pharmaceutical contract development and manufacturing organisation (CDMO), has announced progress on its new sterile manufacturing facility, scheduled to open in early 2026.
- Author: PharmaManufacturing IQ Staff
- Tags: Sterile Manufacturing, News, Facilities & Expansion

**Eramol, a UK-based pharmaceutical contract development and manufacturing organisation (CDMO), has announced progress on its new sterile manufacturing facility, scheduled to open in early 2026\.** 

Located in Sevenoaks, Kent, the facility spans 11,000 square feet, including a dedicated 1,900 square foot GMP Grade A/C cleanroom suite designed for small to medium batch production of sterile injectable products. The site will also include modern offices and client reception areas — making it a fully integrated, client-ready environment. 

Eramol’s facility is purpose-built to meet the stringent requirements of the 2023 EU GMP Annex 1, incorporating industry best practices to proactively identify, control, and mitigate contamination risks. Every aspect — from cleanroom layout to environmental monitoring — has been designed to uphold the highest standards of sterility assurance and product quality. The facility will house cutting-edge equipment, including a Fedegari autoclave and high-performance isolator technology, enabling aseptic filling of sterile solutions into 2ml and 10ml vials. The equipment has been carefully selected for performance, reliability, and future scalability, ensuring clients benefit from a seamless transition from early-phase to late-phase or commercial manufacturing.

“This facility reflects our commitment to supporting clients with a flexible, compliant, and forward-thinking approach to sterile manufacturing,” said Peter Mollison, co- CEO and co-founder at Eramol. “We’ve built-in expansion capacity and the agility to scale with our partners to develop long term strategic collaborations.”

The isolator installation is scheduled for October 2025, with commissioning and qualification activities — including autoclave cycle development and performance qualification — underway from September. An MHRA inspection is anticipated by the end of 2025, enabling client onboarding soon after.